Related references
Note: Only part of the references are listed.A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
D. A. Scott et al.
DIABETES OBESITY & METABOLISM (2013)
Evolution of Insulin Development: Focus on Key Parameters
Joseph M. Tibaldi
ADVANCES IN THERAPY (2012)
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2012)
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Odd Erik Johansen et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Vanita R. Aroda et al.
CLINICAL THERAPEUTICS (2012)
Glucagon-Like Peptide-1 and its Cardiovascular Effects
Kyung-Sun Heo et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
R. A. DeFronzo et al.
DIABETES OBESITY & METABOLISM (2012)
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
C. F. Deacon et al.
DIABETES OBESITY & METABOLISM (2012)
GLP-1 based therapies: differential effects on fasting and postprandial glucose
M. S. Fineman et al.
DIABETES OBESITY & METABOLISM (2012)
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
M. S. Fineman et al.
DIABETES OBESITY & METABOLISM (2012)
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
M. Pendergrass et al.
DIABETES OBESITY & METABOLISM (2012)
Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience
Giuseppe Derosa et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Alan J. Garber et al.
LANCET (2012)
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Simon Heller et al.
LANCET (2012)
Glycemic Management of Type 2 Diabetes Mellitus
Faramarz Ismail-Beigi
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Jutta Keller et al.
REGULATORY PEPTIDES (2012)
YIA: basic and translational science
European Journal of Preventive Cardiology (2012)
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation
Emily Jane Gallagher et al.
YEAR IN DIABETES AND OBESITY (2011)
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
Robert Ratner et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies
Steven P. Marso et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
Ralph A. DeFronzo
DIABETES CARE (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Kasia J. Lipska et al.
DIABETES CARE (2011)
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
R. Arechavaleta et al.
DIABETES OBESITY & METABOLISM (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes
A. J. Farmer et al.
DIABETES OBESITY & METABOLISM (2011)
Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: A large population-based study
Marta Baviera et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Encapsulation of Exenatide in Poly-(D,L-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
Mary Beth DeYoung et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
Lixisenatide for type 2 diabetes mellitus
Mikkel Christensen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
Laszlo Hegedus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
THERAPY The second time as farce: rosiglitazone and the regulators
Edwin A. M. Gale
NATURE REVIEWS ENDOCRINOLOGY (2011)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
J. Michael Gaziano et al.
DIABETES CARE (2010)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
Oral insulin - a review of current status
Harish Iyer et al.
DIABETES OBESITY & METABOLISM (2010)
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
Vivian A. Fonseca et al.
DIABETES OBESITY & METABOLISM (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
P. C. Butler et al.
DIABETOLOGIA (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Faramarz Ismail-Beigi et al.
LANCET (2010)
Weighing Risks and Benefits of Liraglutide -- The FDA's Review of a New Antidiabetic Therapy.
Mary Parks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
GENOMIC MEDICINE Genomics, Type 2 Diabetes, and Obesity
Mark I. McCarthy
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Robert Frederich et al.
POSTGRADUATE MEDICINE (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Charles Thomas et al.
CELL METABOLISM (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Exenatide-Associated Ischemic Renal Failure
W. J. Weise et al.
DIABETES CARE (2009)
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes A retrospective cohort study
Rebecca A. Noel et al.
DIABETES CARE (2009)
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
J. Rosenstock et al.
DIABETOLOGIA (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Does diabetes therapy influence the risk of cancer?
U. Smith et al.
DIABETOLOGIA (2009)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull et al.
DIABETOLOGIA (2009)
Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists
Fu Lin et al.
JOURNAL OF MOLECULAR MODELING (2009)
Incretin-based therapies for type 2 diabetes mellitus
Julie A. Lovshin et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Glucose Sensing in L Cells: A Primary Cell Study
Frank Reimann et al.
CELL METABOLISM (2008)
Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway
Allison B. Goldfine
CURRENT OPINION IN CARDIOLOGY (2008)
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
B. Ahren et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Exenatide and Rare Adverse Events
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus
Shari Bolen et al.
ANNALS OF INTERNAL MEDICINE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Devada Singh-Franco et al.
CLINICAL THERAPEUTICS (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Insulin secretagogues, sulfonylurea receptors and K-ATP channels
J Bryan et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
LL Baggio et al.
DIABETES (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
T Heise et al.
DIABETES (2004)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
MR Owen et al.
BIOCHEMICAL JOURNAL (2000)
Share Paper
